Breaking News Instant updates and real-time market news.

NVO

Novo Nordisk

$32.66

0.12 (0.37%)

13:04
11/29/16
11/29
13:04
11/29/16
13:04

Novo Nordisk says achieved primary endpoint in DEVOTE trial

Novo Nordisk announced the headline results from the DEVOTE trial, a long-term, randomized, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba compared to insulin glargine U100 when added to standard of care. In the trial, more than 7,500 people with type 2 diabetes at high risk of major adverse cardiovascular events were treated for a period of approximately two years.The trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events with Tresiba compared to insulin glargine U100. The trial thereby confirmed the results of the DEVOTE interim analysis submitted to the U.S. FDA in March 2015, on the basis of which Tresiba and Ryzodeg 70/30 were approved in the U.S. in September 2015. The primary endpoint of the DEVOTE study was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and showed a hazard ratio of 0.91 in favour of Tresiba relative to insulin glargine U100, with no statistically significant difference between the two treatments. In the trial, Tresiba demonstrated superiority on the secondary confirmatory endpoint of severe hypoglycaemia: 27% fewer patients in the Tresiba treated group experienced an episode of severe hypoglycaemia, resulting in a 40% overall reduction of total episodes of adjudicated severe hypoglycaemia. Furthermore, patients in the Tresiba treated group experienced a 54% relative reduction in the rate of nocturnal severe hypoglycaemia. These differences were all statistically significant. Tresiba appeared to have a safe and well-tolerated profile consistent with previous clinical studies conducted with Tresiba.Novo Nordisk expects to present the detailed results of the DEVOTE trial at a scientific meeting and submit the findings for review with regulatory authorities during the first half of 2017.

  • 29

    Nov

  • 07

    Dec

NVO Novo Nordisk
$32.66

0.12 (0.37%)

09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Outperform
Novo Nordisk upgraded to Outperform from Neutral at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Novo Nordisk initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Novo Nordisk with a Neutral rating and DKK 320 price target.
10/28/16
BOFA
10/28/16
DOWNGRADE
BOFA
Underperform
Novo Nordisk downgraded to Underperform from Neutral at BofA/Merrill
10/31/16
SBSH
10/31/16
DOWNGRADE
SBSH
Neutral
Novo Nordisk downgraded to Neutral from Buy at Citi
Citi analyst Peter Verdult downgraded Novo Nordisk to Neutral citing the ongoing net pricing declines across the company's diabetes portfolio as well as expectations for margin erosion at Biopharmaceuticals due to NovoSeven/Norditropin pressures. The analyst cut his price target for the shares to DKK 260 from DKK 400.

TODAY'S FREE FLY STORIES

09:10
12/06/16
12/06
09:10
12/06/16
09:10
General news
U.S. equities are mostly treading water »

U.S. equities are mostly…

BWLD

Buffalo Wild Wings

$170.85

2.75 (1.64%)

09:08
12/06/16
12/06
09:08
12/06/16
09:08
Hot Stocks
Marcato launches dedicated website to express views on Buffalo Wild Wings »

Marcato Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:07
12/06/16
12/06
09:07
12/06/16
09:07
Hot Stocks
Breaking Hot Stocks news story on Belden, Digi International »

Belden…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAN

Huntington Bancshares

$13.03

0.09 (0.70%)

09:06
12/06/16
12/06
09:06
12/06/16
09:06
Initiation
Huntington Bancshares initiated  »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:06
12/06/16
12/06
09:06
12/06/16
09:06
Hot Stocks
Breaking Hot Stocks news story on Belden, Digi International »

Belden: Offer for Digi…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:05
12/06/16
12/06
09:05
12/06/16
09:05
Hot Stocks
Belden: Digi management, board 'unwilling' to engage in discussions with Belden »

Notes…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCE.A

Forest City

$18.75

0.45 (2.46%)

, FCE.B

Forest City

$19.25

0.56 (3.00%)

09:05
12/06/16
12/06
09:05
12/06/16
09:05
Hot Stocks
Forest City recommends shareholders to eliminate dual-class share structure »

Forest City Realty Trust…

FCE.A

Forest City

$18.75

0.45 (2.46%)

FCE.B

Forest City

$19.25

0.56 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

, DGII

Digi International

$13.65

0.1 (0.74%)

09:05
12/06/16
12/06
09:05
12/06/16
09:05
Hot Stocks
Belden reiterates $13.82 per share offer to Digi International board »

Belden (BDC) announced…

BDC

Belden

$74.99

0.9 (1.21%)

DGII

Digi International

$13.65

0.1 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BW

Babcock & Wilcox

$15.99

0.46 (2.96%)

09:04
12/06/16
12/06
09:04
12/06/16
09:04
Hot Stocks
B&W names D. Paul Scavuzzo Chief Commercial Officer »

Babcock & Wilcox…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

XPLR

Xplore Technologies

$2.31

-0.0124 (-0.53%)

09:04
12/06/16
12/06
09:04
12/06/16
09:04
Hot Stocks
Xplore Technologies receives second rugged tablet follow-on order »

Xplore Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BA

Boeing

$152.16

-0.09 (-0.06%)

09:03
12/06/16
12/06
09:03
12/06/16
09:03
Periodicals
Trump wants to cancel Boeing Air Force One order »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLJ

RLJ Lodging Trust

$23.38

0.86 (3.82%)

09:03
12/06/16
12/06
09:03
12/06/16
09:03
Hot Stocks
RLJ Lodging Trust announces sale of two hotels in NYC for $286M »

RLJ Lodging Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEIC

SEI Investments

$48.16

1.2 (2.56%)

09:03
12/06/16
12/06
09:03
12/06/16
09:03
Hot Stocks
SEI Investments signs three-year contract extension with Veritas Investment »

SEI UK Private Banking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUE

Nucor

$65.10

2.07 (3.28%)

09:02
12/06/16
12/06
09:02
12/06/16
09:02
Hot Stocks
Nucor to acquire Southland Tube for $130M »

Nucor announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSTX

Mast Therapeutics

$0.08

0.0009 (1.08%)

09:01
12/06/16
12/06
09:01
12/06/16
09:01
Hot Stocks
Mast Therapeutics enrolls first patient in Phase 2 study of AIR001 »

Mast Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNSL

Consolidated Communications

$27.21

-1.17 (-4.12%)

09:01
12/06/16
12/06
09:01
12/06/16
09:01
Upgrade
Consolidated Communications rating change  »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NLSN

Nielsen

$42.41

0.34 (0.81%)

09:01
12/06/16
12/06
09:01
12/06/16
09:01
Conference/Events
Nielsen to host 2016 analyst day »

2016 Analyst Day to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

CMG

Chipotle

$396.27

-3.76 (-0.94%)

09:00
12/06/16
12/06
09:00
12/06/16
09:00
Hot Stocks
Chipotle says sales haven't recovered as much as previously expected »

Says "took eye off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

RGSE

Real Goods Solar

$0.51

0.0596 (13.23%)

09:00
12/06/16
12/06
09:00
12/06/16
09:00
Syndicate
Breaking Syndicate news story on Real Goods Solar »

Real Goods Solar files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
12/06/16
12/06
09:00
12/06/16
09:00
General news
U.S. trade deficit widened 17.8% to -$42.6 B in October »

U.S. trade deficit…

REI

Ring Energy

$12.15

-0.81 (-6.25%)

08:59
12/06/16
12/06
08:59
12/06/16
08:59
Syndicate
Ring Energy 6.5M share Spot Secondary priced at $11.50 »

SunTrust and Seaport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NSTG

NanoString

$21.99

-0.15 (-0.68%)

08:59
12/06/16
12/06
08:59
12/06/16
08:59
Recommendations
NanoString analyst commentary  »

NanoString a top growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

T

AT&T

$38.63

0.02 (0.05%)

, TWX

Time Warner

$93.34

-0.46 (-0.49%)

08:57
12/06/16
12/06
08:57
12/06/16
08:57
Hot Stocks
AT&T CEO says Time Warner review should be 'straightforward' »

Says Time Warner (TWX)…

T

AT&T

$38.63

0.02 (0.05%)

TWX

Time Warner

$93.34

-0.46 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

08:56
12/06/16
12/06
08:56
12/06/16
08:56
General news
Redbook Store Sales data reported »

Week of 12/3 Redbook…

TDOC

Teladoc

$18.45

0.5 (2.79%)

08:55
12/06/16
12/06
08:55
12/06/16
08:55
Hot Stocks
Teladoc says reached 100,000 telehealth visits during November »

Teladoc announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.